12 May 2022
R&D Center NovaMedica Innotech has celebrated its 5th anniversary. The Center was created during implementation of the R&D strategy of its parent company NovaMedica (RUSNANO’s portfolio asset), which is 10 years old this year. Innotech does projects under NovaMedica’s own R&D program and offers to its partners services in development of new drugs and in contract manufacturing of solid dosage forms.
19 April 2022
Russian pharmaceutical company NovaMedica (investment project of RUSNANO) has developed and registered an innovative combination of Donepezil and Memantine molecules, which are the basic therapy for dementia associated with Alzheimer's disease. The drug is registered under the name MIOREOL®. This is the first such combination in the Russian market and in the markets of the EAEU and Europe.
29 December 2021
We wish you ghappiness and health in the coming year! May it bring peace, prosperety and success! Congratulations!
25 October 2021
Russian pharmaceutical company NovaMedica announces appointment of Timofey PETROV as the head of the R&D Center NovaMedica Innotech (subsidiary of NovaMedica).
21 September 2021
R&D Center NovaMedica Innotech has successfully passed the audit of the Ministry of Industry and Trade and received a renewed and extended manufacturing license for production of pharmaceutical drugs, which creates new contracting opportunities and, in addition to the already existing services, allows carrying out primary and secondary packaging of biological products.
31 May 2021
Russian pharmaceutical company NovaMedica (part of the RUSNANO portfolio) and the corporation Bayer signed an agreement to provide Bayer with an exclusive license to commercialization of an innovative product developed by NovaMedica, including its manufacturing and promotion.
04 March 2021
R&D Center NovaMedica Innotech (subsidiary of the pharmaceutical company NovaMedica, investment project of RUSNANO) announced release of the first commercial batch of the anti-COVID drug Avifavir® under the partnership with Kromis LLC, joint venture of the Russian Direct Investment Fund (RDIF) and the company ChemRar. NovaMedica Innotech will manufacture 100,000 units of Avifavir per month.
03 March 2021
We have already made a tradition of guided tours to the R&D Center NovaMedica Innotech for our most curious and precious visitors – children who come to see what their mothers and fathers do at work.
24 December 2020
NovaMedica team wishes you Happy Holidays! Harmony and joy to you and your loved ones. We wish you to be cheerful and healthy, creative and enthusiastic!
04 December 2020
Rustam Iksanov, Vice President for R&D at NovaMedica, believes one of the most important trends in development of the modern pharmaceutical market to be supergenerics. He spoke about this in his address at the Russian Pharmaceutical Forum in Moscow.
23 May 2022
23 May 2022
20 May 2022
20 May 2022